GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncopeptides AB (STU:OND) » Definitions » Capex-to-Operating-Income

Oncopeptides AB (STU:OND) Capex-to-Operating-Income : 0.00 (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Oncopeptides AB Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Oncopeptides AB's Capital Expenditure for the three months ended in Mar. 2025 was €0.00 Mil. Its Operating Income for the three months ended in Mar. 2025 was €-5.46 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Oncopeptides AB Capex-to-Operating-Income Historical Data

The historical data trend for Oncopeptides AB's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncopeptides AB Capex-to-Operating-Income Chart

Oncopeptides AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Oncopeptides AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Oncopeptides AB's Capex-to-Operating-Income

For the Biotechnology subindustry, Oncopeptides AB's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncopeptides AB's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncopeptides AB's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Oncopeptides AB's Capex-to-Operating-Income falls into.


;
;

Oncopeptides AB Capex-to-Operating-Income Calculation

Oncopeptides AB's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.031) / -24.733
=N/A

Oncopeptides AB's Capex-to-Operating-Income for the quarter that ended in Mar. 2025 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -5.462
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oncopeptides AB  (STU:OND) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Oncopeptides AB Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Oncopeptides AB's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncopeptides AB Business Description

Traded in Other Exchanges
Address
Vastra Tradgardsgatan 15, Stockholm, SWE, SE-111 53
Oncopeptides AB is a biotech company focused on the research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Conjugate (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It has focused on the development of the product candidate Melflufen (Pepaxti), a peptide-conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Compounds. Melflufen is intended as an effective treatment for hematological cancers and in particular multiple myeloma.

Oncopeptides AB Headlines